The company's survival depends on its ability to raise additional capital and generate positive cash flow from its now Israel-only operations. Watch for the outcome of the proposed SDI acquisition and any further dilutive financings. The November 2026 convertible note provides near-term liquidity but adds significant potential dilution.
Price Chart
Executive Summary
IM Cannabis Corp. reported Q3 2026 revenue from continuing operations of $1.65M, down 68% YoY from $5.08M, and a gross loss of $0.04M vs. a $1.58M gross profit a year ago. Net loss widened to $7.08M from $3.87M. The company completed the sale of its European operations (IMC Holdings) on September 29, 2026, recognized a $2.7M gain, and now operates solely in the Israeli medical cannabis market. The MD&A discloses substantial doubt about going concern, with negative working capital of $5.5M and an accumulated deficit of $284.1M as of September 30, 2026.
Key Financial Metrics
Key Facts
- Q3 2026 revenue from continuing operations was $1.65M, down 68% from $5.08M in Q3 2025.
- Q3 2026 gross loss from continuing operations was $0.04M, vs. gross profit of $1.58M in Q3 2025.
- Q3 2026 net loss was $7.08M ($6.69 per share), vs. net loss of $3.87M ($0.44 per share) in Q3 2025.
- Nine-month 2026 revenue from continuing operations was $8.96M, down 43% from $15.77M in the prior year.
- Nine-month 2026 net loss from continuing operations was $10.83M, vs. $2.59M in the prior year.
- Cash and restricted cash totaled $2.4M as of September 30, 2026, vs. $2.7M at December 31, 2025.
- Working capital deficit was $5.5M as of September 30, 2026.
- The MD&A states substantial doubt about the company's ability to continue as a going concern.
- On September 29, 2026, the company completed the sale of IMC Holdings (European operations) for $3.0M in advance payments and assumption of up to $9.4M in liabilities, recognizing a $2.7M gain.
- On November 4, 2026, the company closed a $1.2M convertible note financing with an institutional investor.
Financial Impact
Q3 2026 revenue declined 68% YoY to $1.65M; net loss widened to $7.08M from $3.87M; cash burn continues with $2.4M cash on hand and a $5.5M working capital deficit.
Risk Factors
- Going concern risk: substantial doubt about ability to continue as a going concern, with negative working capital and ongoing operating losses.
- Dilution risk: multiple convertible notes and warrants outstanding, including the November 2026 note convertible into up to 3.9M shares at $0.61.
- Nasdaq delisting risk: the stock has traded below $1.00 and the company has already used a reverse split within the past year, limiting cure options.
- Concentration risk: the company now operates only in the Israeli medical cannabis market, exposed to geopolitical and regulatory risks.
- Related-party transaction risk: CEO Oren Shuster is counterparty to the Slil transaction and the October 2026 debt settlement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-005212 |
| Exhibit: exhibit_99-2.htm | 0001178913-26-005212 |
| Exhibit: exhibit_99-1.htm | 0001178913-26-005212 |
| Exhibit: exhibit_99-5.htm | 0001178913-26-005212 |
| Exhibit: exhibit_99-4.htm | 0001178913-26-005212 |
| Document: zk2636388.htm | 0001178913-26-005212 |
| Document: 0001178913-26-005212-index-headers.html | 0001178913-26-005212 |
| Document: 0001178913-26-005212-index.html | 0001178913-26-005212 |
| Document: 0001178913-26-005212.txt | 0001178913-26-005212 |
| Earnings Context (Synthetic; results releases only) | 0001178913-26-005212 |
Track record
23 reports on IMCC
9 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +82.97% at T+60 after the Aug 13, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 17, 2026today SC 13G Neutral 4/10 Entry $0.4995 Now $0.4800 −3.90% settles Dec 16
- Nov 13, 20263d ago 6-K Bearish 6/10 Viewing Entry price pending
- Nov 13, 20263d ago Press Release Bearish 6/10 Entry $0.5750 Now $0.4800 +16.52% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5800 Now $0.4800 −17.24% settles Dec 15
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $0.5934 Now $0.4800 +19.11% settles Dec 4
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $0.5934 Now $0.4800 +19.11% settles Dec 4
- Oct 21, 202627d ago EFFECT Neutral 4/10 Entry $1.19 Now $0.4800 −59.66% settles Nov 18
- Oct 2, 20266w ago 6-K Mixed 6/10 Entry $1.94 to $0.7675 Now $0.4800 −75.26% ▼ −60.44% −57.86% vs SPY
- Sep 25, 20267w ago 6-K Bearish 6/10 Entry $2.48 to $0.8400 Now $0.4800 +80.65% ▲ +66.13% +66.10% vs SPY
- Sep 24, 20267w ago 424B5 Bearish 7/10 Entry $3.18 to $0.9250 Now $0.4800 +84.91% ▲ +70.91% +70.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers